Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes

Neuron

Volumn 85, Issue 6, 2015, Pages 1212-1226

  Huang, Brenda ^a   Wei, Wen Jie ^a,b   Wang, Guohao ^a,c   Gaertig, Marta A ^a   Feng, Yue ^a   Wang, Wei ^b   Li, Xiao Jiang ^a,c   Li, Shihua ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MESSENGER RNA; MYELIN PROTEIN; PROTEOLIPID PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; HUNTINGTON PROTEIN, MOUSE; MYELIN GENE REGULATORY FACTOR, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; CORPUS CALLOSUM; CORPUS STRIATUM; DEMYELINATION; DISEASE COURSE; GENE; GENE EXPRESSION; GLIA CELL; HUNTINGTON CHOREA; MRF GENE; MYELINATION; MYRF GENE; NERVE CELL; NERVE FIBER DEGENERATION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; TRANSGENE; ANIMAL; AXON; BRAIN; CYTOLOGY; DISEASE MODEL; DOWN REGULATION; GENETICS; METABOLISM; MOUSE; MUTATION; MYELIN SHEATH; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; AXONS; BRAIN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MUTATION; MYELIN SHEATH; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGODENDROGLIA; TRANSCRIPTION FACTORS;

EID: 84925276050     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.02.026     Document Type: Article

References (60)

1. Bankston A.N., Mandler M.D., Feng Y. Oligodendroglia and neurotrophic factors in neurodegeneration. Neurosci. Bull. 2013, 29:216-228.
2. Bartzokis G., Lu P.H., Tishler T.A., Fong S.M., Oluwadara B., Finn J.P., Huang D., Bordelon Y., Mintz J., Perlman S. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res. 2007, 32:1655-1664.
3. Bohanna I., Georgiou-Karistianis N., Sritharan A., Asadi H., Johnston L., Churchyard A., Egan G. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 2011, 5:171-180.
4. Boulanger J.J., Messier C. From precursors to myelinating oligodendrocytes: contribution of intrinsic and extrinsic factors to white matter plasticity in the adult brain. Neuroscience 2014, 269:343-366.
5. Bradford J., Shin J.Y., Roberts M., Wang C.E., Li X.J., Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependentneurological symptoms. Proc. Natl. Acad. Sci. U S A 2009, 106:22480-22485.
6. Bujalka H., Koenning M., Jackson S., Perreau V.M., Pope B., Hay C.M., Mitew S., Hill A.F., Lu Q.R., Wegner M., et al. MYRF is a membrane-associated transcription factor that autoproteolytically cleaves to directly activate myelin genes. PLoS Biol. 2013, 11:e1001625.
7. Cahoy J.D., Emery B., Kaushal A., Foo L.C., Zamanian J.L., Christopherson K.S., Xing Y., Lubischer J.L., Krieg P.A., Krupenko S.A., et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J.Neurosci. 2008, 28:264-278.
8. Camacho A., Huang J.K., Delint-Ramirez I., Yew Tan C., Fuller M., Lelliott C.J., Vidal-Puig A., Franklin R.J. Peroxisome proliferator-activated receptor gamma-coactivator-1 alpha coordinates sphingolipid metabolism, lipid raft composition and myelin protein synthesis. Eur. J. Neurosci. 2013, 38:2672-2683.
9. Crotti A., Benner C., Kerman B.E., Gosselin D., Lagier-Tourenne C., Zuccato C., Cattaneo E., Gage F.H., Cleveland D.W., Glass C.K. Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 2014, 17:513-521.
10. Di Paola M., Luders E., Cherubini A., Sanchez-Castaneda C., Thompson P.M., Toga A.W., Caltagirone C., Orobello S., Elifani F., Squitieri F., Sabatini U. Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. Cereb. Cortex 2012, 22:2858-2866.
11. Di Paola M., Phillips O.R., Sanchez-Castaneda C., Di Pardo A., Maglione V., Caltagirone C., Sabatini U., Squitieri F. MRI measures of corpus callosum iron and myelin in early Huntington's disease. Hum. Brain Mapp. 2014, 35:3143-3151.
12. Ehrnhoefer D.E., Sutton L., Hayden M.R. Small changes, bigimpact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 2011, 17:475-492.
13. Emery B. Regulation of oligodendrocyte differentiation and myelination. Science 2010, 330:779-782.
14. Emery B., Agalliu D., Cahoy J.D., Watkins T.A., Dugas J.C., Mulinyawe S.B., Ibrahim A., Ligon K.L., Rowitch D.H., Barres B.A. Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell 2009, 138:172-185.
15. Fennema-Notestine C., Archibald S.L., Jacobson M.W., Corey-Bloom J., Paulsen J.S., Peavy G.M., Gamst A.C., Hamilton J.M., Salmon D.P., Jernigan T.L. Invivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004, 63:989-995.
16. Franklin R.J., Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 2008, 9:839-855.
17. Fünfschilling U., Supplie L.M., Mahad D., Boretius S., Saab A.S., Edgar J., Brinkmann B.G., Kassmann C.M., Tzvetanova I.D., Möbius W., et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012, 485:517-521.
18. Fuss B., Mallon B., Phan T., Ohlemeyer C., Kirchhoff F., Nishiyama A., Macklin W.B. Purification and analysis of invivo-differentiated oligodendrocytes expressing the green fluorescent protein. Dev. Biol. 2000, 218:259-274.
19. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., Iwasato T., Itohara S., Li X.J., Mody I., et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
20. Han I., You Y., Kordower J.H., Brady S.T., Morfini G.A. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J.Neurochem. 2010, 113:1073-1091.
21. Harjes P., Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 2003, 28:425-433.
22. Heng M.Y., Detloff P.J., Albin R.L. Rodent genetic models of Huntington disease. Neurobiol. Dis. 2008, 32:1-9.
23. Hornig J., Fröb F., Vogl M.R., Hermans-Borgmeyer I., Tamm E.R., Wegner M. The transcription factors Sox10 and Myrf define an essential regulatory network module in differentiating oligodendrocytes. PLoS Genet. 2013, 9:e1003907.
24. Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013, 16:571-579.
25. Koenning M., Jackson S., Hay C.M., Faux C., Kilpatrick T.J., Willingham M., Emery B. Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS. J.Neurosci. 2012, 32:12528-12542.
26. Lee Y., Morrison B.M., Li Y., Lengacher S., Farah M.H., Hoffman P.N., Liu Y., Tsingalia A., Jin L., Zhang P.W., et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012, 487:443-448.
27. Lee C.Y., Cantle J.P., Yang X.W. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J. 2013, 280:4382-4394.
28. Lee J., Taghian K., Petratos S. Axonal degeneration in multiplesclerosis: can we predict and prevent permanent disability?. Acta Neuropathol. Commun. 2014, 2:97.
29. Li S.H., Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004, 20:146-154.
30. Li X.-J., Li S. Influence of species differences on the neuropathology of transgenic Huntington's disease animal models. J.Genet. Genomics 2012, 39:239-245.
31. Li H., Li S.H., Yu Z.X., Shelbourne P., Li X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J.Neurosci. 2001, 21:8473-8481.
32. Li Z., Park Y., Marcotte E.M. A bacteriophage tailspike domain promotes self-cleavage of a human membrane-bound transcription factor, the myelin regulatory factor MYRF. PLoS Biol. 2013, 11:e1001624.
33. Ligon K.L., Fancy S.P., Franklin R.J., Rowitch D.H. Olig gene function in CNS development and disease. Glia 2006, 54:1-10.
34. Mack J.T., Beljanski V., Soulika A.M., Townsend D.M., Brown C.B., Davis W., Tew K.D. "Skittish" Abca2 knockout mice display tremor, hyperactivity, and abnormal myelin ultrastructure in the central nervous system. Mol. Cell. Biol. 2007, 27:44-53.
35. Makinson C.D., Tanaka B.S., Lamar T., Goldin A.L., Escayg A. Role of the hippocampus in Nav1.6 (Scn8a) mediated seizure resistance. Neurobiol. Dis. 2014, 68:16-25.
36. Mallon B.S., Shick H.E., Kidd G.J., Macklin W.B. Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J.Neurosci. 2002, 22:876-885.
37. McKenzie I.A., Ohayon D., Li H., de Faria J.P., Emery B., Tohyama K., Richardson W.D. Motor skill learning requires active central myelination. Science 2014, 346:318-322.
38. Meijer D.H., Kane M.F., Mehta S., Liu H., Harrington E., Taylor C.M., Stiles C.D., Rowitch D.H. Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2. Nat. Rev. Neurosci. 2012, 13:819-831.
39. Menalled L.B., Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 2002, 23:32-39.
40. Michalski J.P., Anderson C., Beauvais A., De Repentigny Y., Kothary R. The proteolipid protein promoter drives expression outside of the oligodendrocyte lineage during embryonic and early postnatal development. PLoS ONE 2011, 6:e19772.
41. Munoz-Sanjuan I., Bates G.P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J.Clin. Invest. 2011, 121:476-483.
42. Paus T., Zijdenbos A., Worsley K., Collins D.L., Blumenthal J., Giedd J.N., Rapoport J.L., Evans A.C. Structural maturation of neural pathways in children and adolescents: invivo study. Science 1999, 283:1908-1911.
43. Philips T., Bento-Abreu A., Nonneman A., Haeck W., Staats K., Geelen V., Hersmus N., Küsters B., Van Den Bosch L., Van Damme P., et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain 2013, 136:471-482.
44. Phillips O., Squitieri F., Sanchez-Castaneda C., Elifani F., Caltagirone C., Sabatini U., Di Paola M. Deep white matter in Huntington's disease. PLoS ONE 2014, 9:e109676.
45. Rivers L.E., Young K.M., Rizzi M., Jamen F., Psachoulia K., Wade A., Kessaris N., Richardson W.D. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat. Neurosci. 2008, 11:1392-1401.
46. Rodriguez M., Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct. Pathol. 1994, 18:3-13.
47. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
48. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
49. Ross C.A., Aylward E.H., Wild E.J., Langbehn D.R., Long J.D., Warner J.H., Scahill R.I., Leavitt B.R., Stout J.C., Paulsen J.S., et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 2014, 10:204-216.
50. Saher G., Quintes S., Nave K.A. Cholesterol: a novel regulatory role in myelin formation. Neuroscientist 2011, 17:79-93.
51. Sathornsumetee S., McGavern D.B., Ure D.R., Rodriguez M. Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis. Am. J. Pathol. 2000, 157:1365-1376.
52. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J.Cell Biol. 2005, 171:1001-1012.
53. Tong X., Ao Y., Faas G.C., Nwaobi S.E., Xu J., Haustein M.D., Anderson M.A., Mody I., Olsen M.L., Sofroniew M.V., Khakh B.S. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat. Neurosci. 2014, 17:694-703.
54. Valenza M., Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci. 2011, 34:474-486.
55. Vonsattel J.P., DiFiglia M. Huntington disease. J.Neuropathol. Exp. Neurol. 1998, 57:369-384.
56. Wade A., Jacobs P., Morton A.J. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation. Brain Res. 2008, 1188:61-68.
57. Wang C.E., Tydlacka S., Orr A.L., Yang S.H., Graham R.K., Hayden M.R., Li S., Chan A.W., Li X.J. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum. Mol. Genet. 2008, 17:2738-2751.
58. Woodman B., Butler R., Landles C., Lupton M.K., Tse J., Hockly E., Moffitt H., Sathasivam K., Bates G.P. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 2007, 72:83-97.
59. Xiang Z., Valenza M., Cui L., Leoni V., Jeong H.K., Brilli E., Zhang J., Peng Q., Duan W., Reeves S.A., et al. Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. J.Neurosci. 2011, 31:9544-9553.
60. Xu Q., Huang S., Song M., Wang C.E., Yan S., Liu X., Gaertig M.A., Yu S.P., Li H., Li S., Li X.J. Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms. J.Cell Biol. 2013, 202:1123-1138.